 The objectives of this study are to replicate the safety and efficacy of 68Ga-PSMA PETCT and as a diagnostic and decision making tool in the management prostate cancer patients.The primary endpoints of the study are the incidence of adverse events AE in the study population up to 7 days following the scan, and the sensitivity and specificity of 68Ga-PSMA PETCT vs CT on a per-patient and per-lesion basis. 